The class III HDAC inhibitor, nicotinamide – which is able to increase FXN expression in FRDA cell and mouse models – has also been shown to decrease the levels of H3K9me3 and H3K27me3 at the FXN locus (Chan et al., 2013). The gene discussed is FXN; the disease is Friedreich ataxia.